<DOC>
	<DOCNO>NCT01428518</DOCNO>
	<brief_summary>This post-marketing surveillance study design collect ass information safety effectiveness lamotrigine tablet patient bipolar disorder routine clinical practice . ( `` LAMICTAL '' trademark GlaxoSmithKline group company . )</brief_summary>
	<brief_title>Special Drug Use Investigation LAMICTAL Bipolar</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<criteria>Patients bipolar disorder Patients treat lamotrigine tablet first time</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>